REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -0.75 (-3.00%)
Spread: 0.50 (2.083%)
Open: 25.00
High: 25.00
Low: 24.25
Prev. Close: 25.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Henry Boot, Firestone Diamonds, Amino Tech...

Mon, 07th Feb 2011 11:52

Property developer Henry Boot says it will move to a net cash position after it agreed the sale of a shopping centre in Ayr for £33.8m and the sale of land with planning permission to build houses in Buckingham for an undisclosed fee.Henry Boot said last month that one of its goals is to 'manage debt levels prudently.'An update on its Liqhobong mine in Lesotho has sent shares in Firestone Diamonds higher. Mining is to commence this month. Chief executive says the company is well positioned to become a significant diamond producer and reach its target of producing 1m carats a year by 2014.Online video services provider Amino Technologies has slashed full-year losses, as expected, after returning to profitability in the second half. Cambridge-based Amino lost £882,000 in the year ended 30 November compared with an £8.7m deficit the year before. Revenue rose three quarters to £44m."The sales momentum identified at the end of 2009 has continued throughout the year and into 2011 with a strong order book," it said Monday.Software company Corero is raising £2.3m from a placing at 35p a share after agreeing to buy Massachusetts-based Top Layer Networks for up to $15.3m in shares, loan notes and cash. "We are delighted that Top Layer will be our first acquisition and will provide us with the core technology for our move into network security systems - a market that offers significant growth potential," said non-executive Chairman Jens Montanana.Sareum has announced "positive" results from its pre-clinical in-vivo efficacy studies into acute myeloid leukaemia (AML), the most common form of adult leukaemia. "A recent study for Sareum's Aurora+FLT3 Kinase programme showed that the leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated (ten in total) with a Sareum compound," it said. Leukaemia increased five to fifteen fold in the study examples treated without Sareum's compound.Water filters specialist Amiad has acquired the remaining 34% of the issued share capital of its French subsidiary, Amiad France for 69,000 shares.Kyrgyz Republic gold miner Chaarat has conditionally raised approximately £51.6m through a placing and direct subscriptions at 50p per share. "Chaarat is delighted to announce that it has now secured the funding to establish the initial production stage of the Chaarat project and take it to production," Dekel Golan, chief executive, commented. Safety harness specialist Latchways is confident of achieving current market forecasts for the year. "The export-led growth reported in our interim results announcement has continued. Progress has remained positive, with business particularly strong in North America, and we have also added to our worldwide customer basefor vertical systems. The UK construction market has remained subdued, and was adversely affected by the severe December weather."Sable Mining is encouraged by progress at Lubu Coal Concession in north-western Zimbabwe. "The results confirm the potential of Lubu and importantly demonstrate the presence of a coking coal fraction in the Main Seam as well as in three other seams," it said.
More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.